US8935291075 - Common Stock
TRANSCAT INC
NASDAQ:TRNS (11/21/2024, 4:30:01 PM)
After market: 106.79 0 (0%)106.79
+3.96 (+3.85%)
Transcat, Inc. engages in the provision of calibration and laboratory instrument services. The company is headquartered in Rochester, New York and currently employs 1,104 full-time employees. The firm is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, medical device and other FDA-regulated businesses. Through its Service segment, it offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services, a majority of which are processed through its asset management system, CalTrak, and its online customer portal, C3. The company also provides permanent and periodic onsite services, mobile calibration services, pickup and delivery and in-house services. Through its Distribution segment, it sells and rents national and proprietary brand instruments to customers globally.
TRANSCAT INC
35 Vantage Point Dr
Rochester NEW YORK 14624
P: 15853527777
CEO: Lee D. Rudow
Employees: 1104
Website: https://www.transcat.com/
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how WESCO (NYSE:WCC) and the rest of the maintenance and repair distributors stocks fared in Q3.
Shares of measurement equipment distributor Transcat (NASDAQ:TRNS) fell 13.9% in the morning session after the company reported underwhelming third-quarter earnings results, with its revenue, EBITDA, and EPS missing Wall Street's estimates. Management attributed the weakness to the deceleration in Service organic revenue growth which fell below historical trends due to a decline in the Nexa cost control and optimization services business. Overall, this was a softer quarter.
Measurement equipment distributor Transcat (NASDAQ:TRNS) fell short of the market’s revenue expectations in Q3 CY2024, but sales rose 8% year on year to $67.83 million. Its GAAP profit of $0.35 per share was also 24.5% below analysts’ consensus estimates.
Here you can normally see the latest stock twits on TRNS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: